The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Recent and future changes in the landscape of AML: the addition of venetoclax and MRD eradication
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses recent and future areas of interest in the treatment of acute myeloid leukemia (AML), including the addition of venetoclax to other treatment regimens to improve response, and the use of measurable residual disease (MRD) as a measure of treatment efficacy and a surrogate endpoint in clinical trials. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Astex/Taiho.
